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Diluted porcine surfactant  
lung lavages in children 
with severe ARDS  
ABSTRACT
Acute respiratory distress syndrome (ARDS) is characterized by damage to the arteriolar-capillary endothelium and alveolar 
epithelium that leads to surfactant deficiency and atelectasis.  Alveolar collapse and pulmonary edema will further induce 
surfactant inactivation. Surfactant supplementation has been suggested but results are unpredictable. Poor response may 
be due to inhibition of administered surfactant by plasma components filling the alveolar space, severity of lung injury, time 
of surfactant application and inadequate dose. We report the course of gas exchange and pulmonary mechanics after insti-
llation  of surfactant in 14 children (3 months-7 years) with severe ARDS, defined as an oxygenation index (OI) > 30 and a 
partial pressure of oxygen/ fraction of Inspired oxygen (PaO2/FiO2) <150 .  We used a diluted concentration of Curosurf 
(8 mg/ml) divided into 4 aliquots, for a total dose of 25 mg/kg. An additional aliquot was used for bronchoalveolar lavage 
before surfactant treatment.  
 All children showed a dramatic response to surfactant with rapid and progressive increase in compliance and improve-
ment of all respiratory mechanics.  Mechanical ventilation settings were rapidly reduced and gas exchange improved with 
a PaO2/FiO2 >200 for more than 12 hours.     
Diluted surfactant lung lavages were able to increase blood gas exchange in all our patients despite previously severe gas 
exchange impairment.
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Introduction
Acute respiratory distress syndrome 
(ARDS) is a lung pathology induced 
by diverse injuries, including trauma, 
sepsis, liquid aspiration, inhaled gases, 
radiation, pneumonitis and many 
others. 
Despite the introduction of new tre-
atments, the mortality from ARDS in 
the pediatric age group remains high 
(about 40%). (1) ARDS is characterized 
by damage to the arteriolar-capillary 
endothelium and alveolar epithelium, 
including type I and type II pneumo-
cytes. (2) Damage to the latter results 
in surfactant deficiency and atelectasis. 
Even though surfactant abnormalities in 
ARDS are not the primary pathogenic 
factor, surfactant deficiency, either in 
the presence or absence of type II pne-
umocyte alterations, may result from 
primary or secondary inhibition or inac-
tivation of pulmonary surfactant in the 
alveolar space. (2,3) Surfactant defici-
ency and inactivation will further indu-
ce alveolar collapse and pulmonary 
edema, leading to the characteristic 
pathophysiology of ARDS. (2,3) 
Surfactant supplementation has been 
suggested but the treatment is unpre-
dictable. (4,5) Poor response may be 
due to inhibition of administered sur-
factant by plasma components filling 
the alveolar space related to the seve-
rity of lung injury. Therefore, the timing 
and modality of surfactant application 
seems very important. (3-5)
In our study we report the course of gas 
exchange and pulmonary mechanics in 
15 children with severe ARDS treated 
with repeated bronchoalveolar lavages 
of diluted natural porcine surfactant 
(Curosurf).
Material and methods
We enrolled all children admitted 
between  January 2005 and December 
2007 to  the Pediatric Intensive Care 
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Units of A. Gemelli University Hospital 
and Bambino Gesù Hospital of Rome 
with  severe ARDS, defined as an OI > 
20 and a PaO2/FiO2 < 150 in patients 
who required more than 12 cmH2O of 
mean alveolar pressure under mecha-
nical ventilation.  Children with chro-
nic lung diseases and major cardiac 
malformations were excluded. This 
group of children with severe ARDS 
was treated with tracheobroncoalve-
olar lavage using a 10 times diluted 
concentration of Curosurf (8 mg/ml). 
Lavage was performed with an instilled 
volume of 3mL/kg of diluted surfactant 
repeated 3 times for a total surfactant 
dose of 24 mg/kg. After 5 hand bagging 
maneuvers, to distribute the solution 
well, deep suction of the airways was 
applied.  A corrected procedure was 
defined as one which reached a reco-
very volume of more than 40%.  As 
soon as the child’s cardiorespiratory 
parameters were stabilized, we instilled 
the same diluted surfactant solution 
used for the lavages through a catheter 
inserted in the endotracheal tube and 
placed the infants in 4 classical decu-
bitus positions. Suctioning was avoi-
ded for the subsequent 2 hours. Gas 
exchange was monitored continuously 
via oxygen saturation, end tidal CO2 
and a transcutaneous monitor.  Heart 
rate, blood pressure, central venous 
pressure and urine output were also 
recorded. Monitoring of all cardiores-
piratory parameters was continuously 
performed during the whole procedure 
and ventilator setting was adjusted to 
keep SO2> 92% and end –tidal CO2 in 
the range between 40-50 mmHg. Pul-
monary function tests were performed 
before, and 30 min, 1 hr ,4 hr, 8 hr,12 hr, 
24 hr, 48 hr and 72 hr after treatment.
Results
The sample consists of fourteen (n=14) 
children. The age of our children ran-
ged between 3 months and 7 years, 
and the origin of ARDS was very diffe-
rent: burn, septic shock, bronchiolitis, 
pulmonary thromboembolism, trauma 
and pleuropneumonia (table 1). Pedi-
atric risk of mortality (PRISM) score 
ranged between 10 and 13 points (table 
1). Mechanical ventilation was set in 
order to reduce baro and volutrauma 
using small tidal volume, high respi-
ratory rate, permissive hypercapnia 
and prone position. Two children were 
under high frequency oscillation ventila-
tion (HFOV). All patients were receiving 
corticosteroid treatment.
Every child showed a dramatic respon-
se to surfactant with rapid and progre-
ssive increase in compliance from a 
mean of 0.43 (range 0.38-0.51) befo-
re surfactant treatment to 0.97(range 
0,85-1.2) cmH2O/ml/kg 12 hours after 
treatment (figure 1). Mean OI dropped 
under 15 (range 5-18) and mean PaO2/
FiO2 increased over 250 (range 216-
260) in less than 6 hours (figure 2). 
Mechanical ventilation set was rapidly 
reduced obtaining a mean (mean arteri-
al pressure) MAP < 10 cmH2O and this 
improvement in gas exchange was kept 
for more than 12 hours (figure 2). After 
that, all patients recorded progressive 
pulmonary deterioration characterized 
by an increase in oxygen supplemen-
tation. In 6 out of 14 children the PaO2/
FiO2 ratio returned to below 150 and 
we re-treated them with a new course 
of diluted surfactant.  The response to 
the second dose was less impressi-
ve and more delayed, but in 48 hours 
all babies increased their PaO2/FiO2 
over 250. All patients were extubated 
Table 1. General clinical characteristics of studied children.
GENERAL  CLINICAL 
CHARACTERISTICS
 Age Gender   ARDS etiology PRISM OI
  1    5 yr   F Burn   13   36
  2    1yr   F Sepsis   12   33
  3    4mo   M Bronchiolitis     10   30
  4    6mo   M Pneumonia    11   30
  5     2yr   M DIC, Meningitis    13   31
  6    6yr   F
Disseminated   
TBC
  12   31
  7    3yr   M Tonsillectomy   13   32
  8    4yr   M
Aspiration 
pneumonia
  13   33
  9    5mo   M Bronchiolitis   10   30
  10    3mo   F Bronchiolitis   11   30
  11    4yr   M Pneumonia   11   31
  12    10mo   F
Aspiration 
pneumonia
  13   34
  13    3mo   M Bronchiolitis   12   32
  14    7yr    F Trauma   10   30
ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; F, 
female; M, male; mo, months; OI, oxygenation index; PRISM, Pediatric Risk of Mortality; TBC, 
tuberculosis; yr, years. 
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and discharged from the intensive care 
unit (ICU) without major complications. 
Only 1 patient, who had severe tubercu-
losis pleuropneumonia and was under 
HFOV, developed a bilateral pneumot-
horax and pneumomediastinum in the 
first hours after surfactant treatment 
(which required surgical drainage).
Discussion
Diluted surfactant lung lavages were 
able to increase blood gas exchange 
in all our patients despite all of them 
suffering from severe ARDS with OI > 
30. This improvement was faster and 
more impressive right after the first than 
the second dose.  Experimental animal 
data have shown strong evidence that 
tracheobronchial lavages with surfac-
tant are extremely efficacious in the 
most severe forms of ARDS in which 
alveolar ventilation is extremely hete-
rogenic and the majority of the alveoli 
are filled with edema proteins. (6-8) 
When regular instillation of exogenous 
surfactant is performed, this distribu-
tion is less homogenic and the small 
amount of surfactant that reaches the 
alveoli surface is rapidly inactivated by 
inflammatory and edema proteins. (6-8) 
This is one of the main reasons why the 
majority of randomized controlled trials 
on surfactant treatment in children with 
ARDS failed to find a beneficial effect. 
A recent meta-analysis  pointed out 
that trials paid special attention to the 
selection of  the population,  type, dosa-
ge, timing  and ways of administrati-
on of surfactant achieving a statistical 
significant effect in surfactant treated 
children in term of reduction of days 
of mechanical ventilation, days of ICU 
stay  and one study also in mortality. 
(9)  Despite the limitations of our study 
(we didn’t have a control population), 
it demonstrates very clearly the impro-
ved distribution and efficacy of diluted 
surfactant using lung lavages. A larger, 
randomized controlled trial is needed to 
confirm this important finding.
Figure 1. Lung compliance before and after treatment.
Figure 2. Gas exchange (mean ± sd) in treated children.
 19www.signavitae.com
REFERENCES
1. Bush A. Up Date in pediatric lung disease 2008. Am J Respir Crit Care Med 2009;179:637-49.
2. Dahlem P, van Aalderen WM, Bos AP. Pediatric acute lung injury. Pediatric Respir Rev 2007;8:348-62.
3. Willson DF, Chess PR, Notter RH. Surfactant for pediatric acute lung injury. Pediatric Clin North Am 2008;55:545-75.
4. Marraro GA, Lucchetti M, Spada C, Galassini E, Giossi M, Piero AM. Selective medicated (normal saline and exogenous surfactant) bron-
choalveolar lavage in severe aspiration syndrome in children. Pediatr Crit Care Med 2007;8:505-6.
5. Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, et al. Multicenter, randomized, controller study of porcine .surfactant in 
severe respiratory syncitial virus-induced respiratory failure. Pediatr Crit Care Med 2002;3:261-6.
6. Meister J, Venkataraman B, Ramirez M, Uyehara FT, Killeen J, Ku T, et al. Lavage administration of diluted surfactant in a piglet model of 
meconium aspiration. Lung 2004;182:227-40.
7.  Gommers D, Eijking P, So Kl, van’t Veen A, Lachmann B. Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant 
instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS). Intensive Care 
Med 1998;24:494-500.
8.   Cochrane G, Revak S. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest 1999;116:85-6.
9. Duffett M, Choong K, Ng V, Randolph A, Cook DJ. Surfactant therapy for acute respiratory failure in children: a systematic review and 
meta-analysis. Crit Care 2007;11:66. 
